Hematopoietic Stem Cell TransplantationTransplantation, HomologousStem Cell TransplantationGraft vs Host DiseaseTransplantation ConditioningBone Marrow TransplantationBone MarrowTransplantation, AutologousPeripheral Blood Stem Cell TransplantationHematologic NeoplasmsBone Marrow CellsTissue DonorsTransplantation ChimeraStem CellsTreatment OutcomeGraft vs Leukemia EffectBusulfanMyeloablative AgonistsRemission InductionRecurrenceVidarabineGraft vs Tumor EffectHematopoietic Stem CellsGraft SurvivalHistocompatibility TestingLeukemiaLeukemia, Myeloid, AcuteMultiple MyelomaLymphocyte TransfusionImmunosuppressive AgentsBone and BonesWhole-Body IrradiationRetrospective StudiesCombined Modality TherapyLeukemia, Myelogenous, Chronic, BCR-ABL PositiveCord Blood Stem Cell TransplantationCytomegalovirus InfectionsMyelodysplastic SyndromesSiblingsDisease-Free SurvivalSalvage TherapyLymphocyte DepletionSurvival AnalysisMinor Histocompatibility AntigensLiver TransplantationHistocompatibilityPrecursor Cell Lymphoblastic Leukemia-LymphomaSurvival RateNeoplasm, ResidualAntilymphocyte SerumTime FactorsVirus ActivationCyclophosphamideMelphalanAntineoplastic Combined Chemotherapy ProtocolsChimerismAnemia, AplasticT-LymphocytesMesenchymal Stem Cell TransplantationHepatic Veno-Occlusive DiseaseHematopoietic Stem Cell MobilizationAntigens, CD34Primary MyelofibrosisAcute DiseaseCytomegalovirusHematologic DiseasesFollow-Up StudiesLiving DonorsCell TransplantationKidney TransplantationHLA AntigensPrognosisCell DifferentiationLeukemia, MyeloidImmunosuppressionCytarabineTransplantation ImmunologyLeukemia, Myeloid, Accelerated PhaseEmbryonic Stem CellsBlood DonorsBone Marrow DiseasesAntineoplastic AgentsFlow CytometryGranulocyte Colony-Stimulating FactorAntibodies, NeoplasmLymphoproliferative DisordersAdult Stem CellsImmunocompromised HostBenzamidesFusion Proteins, bcr-ablGraft RejectionHodgkin DiseaseRoseolovirus InfectionsCells, CulturedHematopoiesisLymphoma, Non-HodgkinMice, Inbred C57BLNuclear FamilyPyrimidinesFatal Outcome